Abstract

Atypical chronic myeloid leukemia is a rare entity that presents diagnostic and therapeutic challenges. Traditionally utilized therapeutic agents such as hydroxyurea or interferon result in a median survival of approximately two years, thus warranting identification of better options. We report a 49-year-old Caucasian female, who presented with extreme leukocytosis (white blood cells of 148,300/μL) with left shift, severe anemia, and thrombocytopenia. Following a diagnosis of atypical chronic myeloid leukemia, she was started on intravenous decitabine. She subsequently developed paraneoplastic vasculitis of large arteries, which responded to high-dose glucocorticoid. Decitabine therapy resulted in an excellent hematologic response, transfusion independence, and successful transition to an allogeneic peripheral stem cell transplantation. However, the patient subsequently succumbed to the complications of acute graft-versus-host-disease. This case illustrates an association between atypical chronic myeloid leukemia and steroid-responsive paraneoplastic vasculitis and highlights the single-agent disease activity of decitabine in atypical chronic myeloid leukemia, which may be utilized as a bridging therapy to allogeneic stem cell transplantation.

Original languageEnglish (US)
Pages (from-to)790-794
Number of pages5
JournalJournal of Oncology Pharmacy Practice
Volume22
Issue number6
DOIs
StatePublished - Dec 1 2016

Fingerprint

decitabine
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Vasculitis
Peripheral Blood Stem Cell Transplantation
Hydroxyurea
Leukocytosis
Stem Cell Transplantation
Graft vs Host Disease
Therapeutics
Thrombocytopenia
Interferons
Glucocorticoids
Anemia
Leukocytes
Arteries
Steroids
Survival

Keywords

  • Atypical chronic myeloid leukemia
  • decitabine
  • hematopoietic stem cell transplant
  • paraneoplastic vasculitis

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

@article{fcc6f7593d90428085d92bc525641ac3,
title = "Activity of single-agent decitabine in atypical chronic myeloid leukemia",
abstract = "Atypical chronic myeloid leukemia is a rare entity that presents diagnostic and therapeutic challenges. Traditionally utilized therapeutic agents such as hydroxyurea or interferon result in a median survival of approximately two years, thus warranting identification of better options. We report a 49-year-old Caucasian female, who presented with extreme leukocytosis (white blood cells of 148,300/μL) with left shift, severe anemia, and thrombocytopenia. Following a diagnosis of atypical chronic myeloid leukemia, she was started on intravenous decitabine. She subsequently developed paraneoplastic vasculitis of large arteries, which responded to high-dose glucocorticoid. Decitabine therapy resulted in an excellent hematologic response, transfusion independence, and successful transition to an allogeneic peripheral stem cell transplantation. However, the patient subsequently succumbed to the complications of acute graft-versus-host-disease. This case illustrates an association between atypical chronic myeloid leukemia and steroid-responsive paraneoplastic vasculitis and highlights the single-agent disease activity of decitabine in atypical chronic myeloid leukemia, which may be utilized as a bridging therapy to allogeneic stem cell transplantation.",
keywords = "Atypical chronic myeloid leukemia, decitabine, hematopoietic stem cell transplant, paraneoplastic vasculitis",
author = "Heidi Hausmann and Bhatt, {Vijaya R} and Ji Yuan and Maness-Harris, {Lori J} and Ganti, {Apar Kishor P}",
year = "2016",
month = "12",
day = "1",
doi = "10.1177/1078155215605662",
language = "English (US)",
volume = "22",
pages = "790--794",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Activity of single-agent decitabine in atypical chronic myeloid leukemia

AU - Hausmann, Heidi

AU - Bhatt, Vijaya R

AU - Yuan, Ji

AU - Maness-Harris, Lori J

AU - Ganti, Apar Kishor P

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Atypical chronic myeloid leukemia is a rare entity that presents diagnostic and therapeutic challenges. Traditionally utilized therapeutic agents such as hydroxyurea or interferon result in a median survival of approximately two years, thus warranting identification of better options. We report a 49-year-old Caucasian female, who presented with extreme leukocytosis (white blood cells of 148,300/μL) with left shift, severe anemia, and thrombocytopenia. Following a diagnosis of atypical chronic myeloid leukemia, she was started on intravenous decitabine. She subsequently developed paraneoplastic vasculitis of large arteries, which responded to high-dose glucocorticoid. Decitabine therapy resulted in an excellent hematologic response, transfusion independence, and successful transition to an allogeneic peripheral stem cell transplantation. However, the patient subsequently succumbed to the complications of acute graft-versus-host-disease. This case illustrates an association between atypical chronic myeloid leukemia and steroid-responsive paraneoplastic vasculitis and highlights the single-agent disease activity of decitabine in atypical chronic myeloid leukemia, which may be utilized as a bridging therapy to allogeneic stem cell transplantation.

AB - Atypical chronic myeloid leukemia is a rare entity that presents diagnostic and therapeutic challenges. Traditionally utilized therapeutic agents such as hydroxyurea or interferon result in a median survival of approximately two years, thus warranting identification of better options. We report a 49-year-old Caucasian female, who presented with extreme leukocytosis (white blood cells of 148,300/μL) with left shift, severe anemia, and thrombocytopenia. Following a diagnosis of atypical chronic myeloid leukemia, she was started on intravenous decitabine. She subsequently developed paraneoplastic vasculitis of large arteries, which responded to high-dose glucocorticoid. Decitabine therapy resulted in an excellent hematologic response, transfusion independence, and successful transition to an allogeneic peripheral stem cell transplantation. However, the patient subsequently succumbed to the complications of acute graft-versus-host-disease. This case illustrates an association between atypical chronic myeloid leukemia and steroid-responsive paraneoplastic vasculitis and highlights the single-agent disease activity of decitabine in atypical chronic myeloid leukemia, which may be utilized as a bridging therapy to allogeneic stem cell transplantation.

KW - Atypical chronic myeloid leukemia

KW - decitabine

KW - hematopoietic stem cell transplant

KW - paraneoplastic vasculitis

UR - http://www.scopus.com/inward/record.url?scp=84993949390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993949390&partnerID=8YFLogxK

U2 - 10.1177/1078155215605662

DO - 10.1177/1078155215605662

M3 - Article

C2 - 26378157

AN - SCOPUS:84993949390

VL - 22

SP - 790

EP - 794

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 6

ER -